Company Statements 2019 Archives

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Company Statements 2019

U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru

U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged

U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru

Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia

Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification

Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan

Biocon Facility Completes Pre Approval U.S. FDA Inspection

Biocon Facilities complete Pre Approval U.S. FDA lnspection